Neurovalens is a global health-tech company that creates non-invasive neurostimulation products used to solve some of the world’s greatest health challenges.

Our medical device technology offers unparralleded transdermal activation of the homeostatic nuclei of the brainstem and hypothalamus, allowing for alterations in autonomic function, circadian regulation and Neuro-metabolic influence.

Our core values hinge on the generation of robust clinical data that provide meaningful outcomes throughout the lives of our parents. Neurovalens technology aims to provide drug-free solutions to the worlds greatest health epidemics.

Groundbreaking Neuroscience

Neurovalens has designed cranial nerve stimulation technology that accurately and efficiently activates key brainstem neurons without needing implanted electrodes.

This non-invasive approach removes the need for surgical implantation and allows much earlier intervention in the treatment pathway.

Ultimately, Neurovalens’ technology improves patient lives by reducing costs, reducing risk, and crucially improving the disease pathway to allow significantly better health outcomes.

01001110 01101111 01101110 00100000 01101001 01101110 01110110 01100001 01110011 01101001 01110110 01100101 00100000 01101110 01100101 01110101 01110010 01101111 00100000 01110011 01110100 01101001 01101101 01110101 01101100 01100001 01110100 01101001 01101111 01101110 00100000 01110110 01101001 01100001 00100000 01110100 01101000 01100101 00100000 01101000 01111001 01110000 01101111 01110100 01101000 01100001 01101100 01100001 01101101 01110101 01110011 00100000 01100001 01101110 01100100 00100000 01100010 01110010 01100001 01101001 01101110 00100000 01110011 01110100 01100101 01101101

Neurostimulation Reinvented

Neurovalens technology can be utilized across a wide range of disease processes. Our current focus is to provide drug-free treatments within four key health epidemics.

Obesity

Primary Target:
Arcuate Nucleus (Hypothalamus)

Secondary Target:
Nucleus of the Solitary Tract (Brainstem)

Poor regulation of metabolic homeostasis drives the development of obesity. Neurovalens targets key hypothalamic and brainstem nuclei involved in the neuro-regulation of body composition, with the aim of improving this dysregulation at source.

Diabetes

Primary Target:
Central Melanocortin System (CMCS) (Hypothalamus)

Secondary Target:
Dorsal Motor Nucleus of Vagus (Brainstem)

Our goal in type 2 diabetes is to improve glucose and insulin regulation and therefore positively influence HbA1c. Optimization of the central melanocortin system and regulation of the vagal nerve afferents are the primary target areas to allow better glycemic control and potentially reduce the need for pharmaceuticals.

Insomnia

Primary Target:
Suprachiasmatic Nucleus (SCN) (Hypothalamus)

Secondary Target:
Intergeniculate Leaflet (IGL) (Thalamus)

Homeostatic centres within the hypothalamus and thalamus regulate the circadian rhythm the and sleep wake cycle. Neurovalens’ technology actively stimulates the SCN and IGL in a way that improves both sleep quality and duration

Anxiety

Primary Target:
Locus Coeruleus (LC) (Brainstem)

Secondary Target:
Paraventricular Nucleus (PVN) (Hypothalamus)

Regulation of the parasympathetic and sympathetic pathwyas of the autonomic nervous system in response to stress can be influenced via the LC and the PVN. Connections to these centers via the medial vestibular nucleus allow both to be non-invasively targeted.

Together, science and technology have tremendous potential to improve the lives of billions of people across the world. This understanding is core to the mission of Neurovalens. Our passionate and talented team is dedicated to providing neuro-technology that will help solve the key health problems of our generation.

Dr Jason McKeown
CEO & Co-Founder of Neurovalens

Culture & Process

At Neurovalens, we are very passionate about the technology that we create, and we are extremely proud that this ultimately improves the lives of those who suffer from neurological and metabolic health issues.

The culture of Neurovalens is centred around building value through innovation in medical technology.

Investors

Wharton Asset Management Company

Wharton Asset Management Company is a private single family office established in London in 1992. Wharton looks after a diversified direct global venture capital and private equity portfolio with investments in sectors ranging from highly innovative biotech/life science and high tech (particularly AI) to more traditional consumer goods. Current portfolio spreads across US, Canada, Africa, Europe and all the way to Pakistan.

IQ Capital

IQ Capital is a venture capital firm, based between Cambridge and London, that invests in ‘deep-tech’ across sectors including machine learning, AI, robotics, and advanced engineering and materials, and data-focused propositions based on disruptive algorithms. All of the firm’s portfolio companies are capable of dominating their respective markets on a global scale. Initial investments range from £300k to £5m, with capacity for follow-on investment up to £30m.

The IQ Capital team has achieved over 20 exits to date, to companies including Oracle, Google, Apple, Huawei, and Facebook, and several IPOs. IQ Capital has led 28 investments over the last three years. The firm is currently investing at seed and Series A stage from its third venture fund.

Claredon

Clarendon Fund Managers is one of Belfast’s longest established venture capital fund managers.  It manages CoFundNI which is a £50M equity fund that has co-invested alongside private investors into over 60 Northern Ireland companies.

Angel Co Fund

Angel CoFund (ACF) is an active venture capital fund partnering with experienced syndicates of angel investors to help fund and scale early-stage businesses. Built on the experience of many investments it is a champion of accomplished, hands-on investors who know their sector inside out, and works in partnership with them to provide the capital, experience and support high-potential businesses need. ACF understands that achieving commercial success usually requires time and hence makes long-term investments to help companies reach their full potential and generate higher returns.

Techstart

Techstart Ventures is an early-stage technology investor, managing £90m of funds from offices in Edinburgh and Belfast. Techstart is one of the most active investors in the UK market, completing more than 20 new investments per year.

Beltrae Partners Ltd

Beltrae Partners Ltd (‘Beltrae’) is an all-Ireland CF and private equity firm. Beltrae does not operate a formal managed fund, instead its investment monies are provided by the Directors of Beltrae and, where appropriate, through partnering with HWNI’s, VC’s, professional contacts and trade partners. Beltrae has, to date, acquired majority and minority shareholdings in nineteen businesses in Ireland from which they have exited 10 of these. Their investment holding period has ranged from 5-11 years.

The investee companies employ over 400 people in Ireland, and cover a range of sectors from engineering and distribution, to services, healthcare and media. The total investment to-date in these businesses is in excess of £50m.

Research Associates

Robust clinical data is the cornerstone of Neurovalens approach to treating diseases. We are proud to be collaborating with many world renowned research facilities.

UCSD

Neurovalens has an ongoing research collaboration with the University of California, San Diego (USA). Currently clinical trials are being carried out with the aim of achieving FDA & MHRA approval for the technology to be used in the management of obesity.

Queens University

Both Dr Jason McKeown & Dr Paul D. McGeoch currently hold academic affiliations with Queen’s University Belfast (UK). This collaboration focuses on the influence of Neurovalens’ technology on the influence of metabolism & body composition.

Ulster University

Neurovalens has an ongoing research collaboration with the University of Ulster (UK). Currently clinical trials are being carried out with the aim of achieving FDA & MHRA approval for the technology to be used in the management of obesity.

Le Bonheur Childrens Hospital

Le Bonheur Children’s Hospital (USA) is a world leading authority on paediatric metabolic disease. During 2020 clinical trials to assess the use of Neurovalens’ technology as a treatment for children who suffer from obesity & type 2 diabetes will be carried out.

UCD

Neurovalens has an ongoing research collaboration with the University College Dublin (IRE). Currently clinical trials are being carried out with the aim of achieving HPRA & MHRA approval for the technology to be used in the management of both obesity & type 2 diabetes.

RGD medical college

RDG Medical College (India) has provided invaluable insight into the effects of vestibular nerve stimulation in the settings of insomnia and Type 2 diabetes. Currently clinical trials are being carried out to assess the use of Neurovalens technology within the areas of anxiety and disrupted sleep.

Timeline

2019

• US Patent: Sleep

• Modius SLEEP launch on Indiegogo

2018

• Amazon UK, DE and US launch

• Awards Recieved: Start-Up World Cup, Yahoo Sports Tech Awards, [email protected]

2017

• EU, China & Canada patent

• Modius SLIM: $2M in sales on IndieGoGo

• Official Modius SLIM launch at CES

2016

• US patent

• FDA & MHRA authorization

• Modius SLIM allowed to be sold as a wellness device

2015

• Neurovalens is formed

• UCSD pilot studies

• Awarded Propel Start-up Company of the Year by Invest NI

Our Awards

Health Category at the Future Planet Awards2019

Finalist for Med Tech Innovator Award2019

Finalist UK Business Angel Investment Awards2019

CES Innovation Award2018

Last Gadget Standing Finalist2018

Regional Champion & World Cup Finalist2018

Start-up Entrepreneur of the Year2018

Digital DNA Startup of the Year2018

Weight Management Product of the Year2018

Best New Innovation Yahoo Sports Technology Awards2018

Healthcare Business of the Year2018

Eagle Labs Innovation Award2018